|
⚲
|
| Xanodyne Pharmaceuticals Inc | |
|---|---|
| Firm | |
| Fund # | |
| CIK # | 0001335480 |
| Sale | 2009-05-15 ($87.8 M Offered, $87.8 M Sold) |
| Fund | |
| Phone | 8593717581 |
| Address | One Riverfront Place Newport, 41071 |
| Source | [EDGAR] |
| Fund AUM and Sold ($M) |
|---|
| Fund Details | |
|---|---|
| Director | |
| Custodian | |
| Auditor | |
| Marketer | |
| Broker | |
| Jurisdiction |
| Comparable Firms | State | AUM ($B) |
|---|---|---|
|
Advent Partners LAPEF VII-A Limited Partnership
✚
|
0.0 | |
|
Ad Ventures DFKY, a Series of Ad Ventures Master Fund, LLC
✚
|
0.0 | |
|
Advisors Equity LLC
✚
|
0.0 | |
|
EQT AB (publ)
✚
|
0.0 | |
|
Severance William
✚
|
0.0 | |
|
Severson Mark A
✚
|
0.0 | |
|
SE VII DHC AIV Feeder, L.P.
✚
|
0.0 | |
|
SE VII DHC AIV LP
✚
|
0.0 | |
|
Sevo Nutraceuticals, Inc.
✚
|
0.0 | |
|
Advent Partners AGT-B Cayman Limited Partnership
✚
|
0.0 |